135 related articles for article (PubMed ID: 37774070)
1. Validation of Faecal Pyruvate Kinase Isoenzyme Type M2 (Faecal M2PK Quick) Test in Detection of Colorectal Adenoma and Adenocarcinoma Among High-Risk Malaysian Population.
Mohd Suan MA; Ng YZ; Henry GF; Md Said R; Kollanthavelu S; Mustapha MI; Hoe CH; Lee CK; Rajamanickam P; Ismail I; Chan HK; Abu Hassan MR
Asian Pac J Cancer Prev; 2023 Sep; 24(9):3183-3186. PubMed ID: 37774070
[TBL] [Abstract][Full Text] [Related]
2. The value of fecal tumor M2 pyruvate kinase as a diagnostic tool for colorectal cancer screening.
Abdullah M; Rani AA; Simadibrata M; Fauzi A; Syam AF
Acta Med Indones; 2012 Apr; 44(2):94-9. PubMed ID: 22745138
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Fecal M2PK as a Diagnostic Marker in Colorectal Cancer.
Dabbous HK; Mohamed YAE; El-Folly RF; El-Talkawy MD; Seddik HE; Johar D; Sarhan MA
J Gastrointest Cancer; 2019 Sep; 50(3):442-450. PubMed ID: 29626277
[TBL] [Abstract][Full Text] [Related]
4. Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening: a meta-analysis.
Tonus C; Sellinger M; Koss K; Neupert G
World J Gastroenterol; 2012 Aug; 18(30):4004-11. PubMed ID: 22912551
[TBL] [Abstract][Full Text] [Related]
5. KRAS mutations and M2PK upregulation in stool samples from individuals with positive fecal occult blood tests screened for colorectal cancer.
Battaglia P; Baritono E; Remo A; Vendraminelli R; Conti A
Tumori; 2014; 100(2):122-7. PubMed ID: 24852854
[TBL] [Abstract][Full Text] [Related]
6. The Diagnostic Accuracy of the M2 Pyruvate Kinase Quick Stool Test--A Rapid Office Based Assay Test for the Detection of Colorectal Cancer.
Sithambaram S; Hilmi I; Goh KL
PLoS One; 2015; 10(7):e0131616. PubMed ID: 26158845
[TBL] [Abstract][Full Text] [Related]
7. Comparison of faecal M2-PK and FIT in a population-based bowel cancer screening cohort.
Leen R; Seng-Lee C; Holleran G; O'Morain C; McNamara D
Eur J Gastroenterol Hepatol; 2014 May; 26(5):514-8. PubMed ID: 24699725
[TBL] [Abstract][Full Text] [Related]
8. A combination of faecal tests for the detection of colon cancer: a new strategy for an appropriate selection of referrals to colonoscopy? A prospective multicentre Italian study.
Parente F; Marino B; Ilardo A; Fracasso P; Zullo A; Hassan C; Moretti R; Cremaschini M; Ardizzoia A; Saracino I; Perna F; Vaira D
Eur J Gastroenterol Hepatol; 2012 Oct; 24(10):1145-52. PubMed ID: 22735608
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy comparison among high risk factors questionnaire and Asia-Pacific colorectal screening score and their combinations with fecal immunochemical test in screening advanced colorectal tumor].
Zhu N; Huang YQ; Song YM; Zhang SZ; Zheng S; Yuan Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Jul; 25(7):612-620. PubMed ID: 35844124
[No Abstract] [Full Text] [Related]
10. Comparison of a New-generation Fecal Immunochemical Test (FIT) With Guaiac Fecal Occult Blood Test (gFOBT) in Detecting Colorectal Neoplasia Among Colonoscopy-referral Patients.
Guimarães DP; Fregnani JH; Reis RM; Taveira LN; Scapulatempo-Neto C; Matsushita M; Silva SRM; Oliveira CZ; Longatto-Filho A; Eklund C; Paloheimo L; Mauad E; Suovaniemi O; Syrjänen K
Anticancer Res; 2019 Jan; 39(1):261-269. PubMed ID: 30591467
[TBL] [Abstract][Full Text] [Related]
11. Screening for colorectal cancer and advanced colorectal neoplasia in kidney transplant recipients: cross sectional prevalence and diagnostic accuracy study of faecal immunochemical testing for haemoglobin and colonoscopy.
Collins MG; Teo E; Cole SR; Chan CY; McDonald SP; Russ GR; Young GP; Bampton PA; Coates PT
BMJ; 2012 Jul; 345():e4657. PubMed ID: 22833618
[TBL] [Abstract][Full Text] [Related]
12. The multitarget fecal immunochemical test versus the fecal immunochemical test for programmatic colorectal cancer screening: a cross-sectional intervention study with paired design.
Wisse PHA; de Klaver W; van Wifferen F; Meiqari L; Bierkens M; Greuter MJE; Carvalho B; van Leerdam ME; Spaander MCW; Dekker E; Coupé VMH; de Wit M; Meijer GA
BMC Cancer; 2022 Dec; 22(1):1299. PubMed ID: 36503495
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity and specificity of faecal tumour M2 pyruvate kinase for detection of colorectal adenomas in a large screening study.
Haug U; Hundt S; Brenner H
Br J Cancer; 2008 Jul; 99(1):133-5. PubMed ID: 18542075
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the Performance of a Fecal Tumor M2-PK Rapid Kit Using Stool Specimens for Detection of Colorectal Tumors.
Cho CH; Kim J; Jang MA; Lee BJ; Park JJ; Lim CS
Ann Clin Lab Sci; 2016; 46(2):154-60. PubMed ID: 27098621
[TBL] [Abstract][Full Text] [Related]
15. Molecular stool testing as an alternative for surveillance colonoscopy: a cross-sectional cohort study.
van Lanschot MC; Carvalho B; Coupé VM; van Engeland M; Dekker E; Meijer GA
BMC Cancer; 2017 Feb; 17(1):116. PubMed ID: 28173852
[TBL] [Abstract][Full Text] [Related]
16. Correlation between Faecal Tumour M2 Pyruvate Kinase and Colonoscopy for the Detection of Adenomatous Neoplasia in a Secondary Care Cohort.
Bond AD; Burkitt MD; Sawbridge D; Corfe BM; Probert CS
J Gastrointestin Liver Dis; 2016 Mar; 25(1):71-7. PubMed ID: 27014756
[TBL] [Abstract][Full Text] [Related]
17. Faecal biomarkers do not always identify pre-cancerous lesions in patients who present in primary care with bowel symptoms.
Keenan J; Aitchison A; Leaman J; Pearson J; Frizelle F
N Z Med J; 2019 Aug; 132(1501):48-56. PubMed ID: 31465327
[TBL] [Abstract][Full Text] [Related]
18. Comparison of an established simple office-based immunological FOBT with fecal tumor pyruvate kinase type M2 (M2-PK) for colorectal cancer screening: prospective multicenter study.
Shastri YM; Loitsch S; Hoepffner N; Povse N; Hanisch E; Rösch W; Mössner J; Stein JM
Am J Gastroenterol; 2008 Jun; 103(6):1496-504. PubMed ID: 18510609
[TBL] [Abstract][Full Text] [Related]
19. Colorectal cancer detection in an asymptomatic population: fecal immunochemical test for hemoglobin vs. fecal M2-type pyruvate kinase.
Caviglia GP; Cabianca L; Fagoonee S; Gili FM
Biochem Med (Zagreb); 2016; 26(1):114-20. PubMed ID: 26981025
[TBL] [Abstract][Full Text] [Related]
20. Prospective multicenter evaluation of fecal tumor pyruvate kinase type M2 (M2-PK) as a screening biomarker for colorectal neoplasia.
Shastri YM; Naumann M; Oremek GM; Hanisch E; Rösch W; Mössner J; Caspary WF; Stein JM
Int J Cancer; 2006 Dec; 119(11):2651-6. PubMed ID: 16929517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
